Olaparib Granted Breakthrough Therapy Designation for mCRPC

Share this content:
The FDA has granted Breakthrough Therapy designation to olaparib (Lynparza) for metastatic castration-resistant prostate cancer.
The FDA has granted Breakthrough Therapy designation to olaparib (Lynparza) for metastatic castration-resistant prostate cancer.

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olaparib (Lynparza), an oral poly ADP-ribose polymerase (PARP) inhibitor, for monotherapy treatment of BRCA1/2 or ATM gene mutated metastatic castration-resistant prostate cancer (mCRPC) in patients who received a prior taxane-based chemotherapy and at least one newer hormonal agent.1

Olaparib was given the designation based on results of the TOPARP-A phase 2 trial. Results from the trial were presented at the American Association for Cancer Research 2015 meeting and published in the New England Journal of Medicine in October 2015.

Researchers found that men with mCRPC with defective DNA damage repair mechanisms responded to olaparib, and that monotherapy with the drug may offer improvement over available therapies for treatment in the biomarker-selected population.

RELATED: Enzalutamide May Be Better Than Bicalutamide for Asymptomatic, Mildly Symptomatic mCRPC

“The Breakthrough Therapy designation for Lynparza is encouraging news for patients and their families, as there are currently very limited treatment options for mCRPC,” said Antoine Yver, Head of Oncology at AstraZeneca.

Olaparib has already been approved by regulatory authorities in 40 countries as maintenance treatment of women with BRCA-mutated ovarian cancer.

Reference

  1. Lynparza™ (olaparib) granted Breakthrough Therapy designation by US FDA for treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer [news release]. AstraZeneca. January 28, 2016. https://www.astrazeneca.com/our-company/media-centre/press-releases/2016/Lynparza-Olaparib-granted-Breakthrough-Therapy-Designation-by-US-FDA-for-treatment-of-BRCA1-2-or-ATM-gene-mutated-metastatic-Castration-Resistant-Prostate-Cancer-28012016.html#main. Accessed February 1, 2016.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters